invIOs to present at Biotech Showcase
December 14, 2022 08:00 ET
|
invIOs GmbH
VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter...
Prolocor to Participate at Biotech Showcase 2022
January 10, 2022 09:00 ET
|
Prolocor Inc
PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Prolocor Inc, a healthcare startup developing an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets, today...
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
January 10, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
INVECTYS INC. TO PARTICIPATE IN THE 2022 JP MORGAN HEALTHCARE MEETING AND BIOTECH SHOWCASE, JANUARY 10-19, 2022
January 05, 2022 09:00 ET
|
Invectys, Inc.
Houston, Texas, USA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
December 23, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™
December 14, 2021 08:18 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), with a mission to discover and develop innovative and revolutionary...
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
January 11, 2021 07:46 ET
|
Cyclacel
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by...
Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance
January 05, 2021 09:44 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
December 30, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
January 13, 2020 07:00 ET
|
Cyclacel
– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML/MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. ...